The METTL1 antibody is a key tool for studying the methyltransferase-like 1 (METTL1) protein, a critical enzyme involved in RNA modification. METTL1. in complex with its cofactor WDR4. catalyzes the transfer of methyl groups to RNA molecules, particularly N7-methylguanosine (m7G) modifications on transfer RNAs (tRNAs). These modifications are essential for maintaining tRNA stability, structural integrity, and translational efficiency. Dysregulation of METTL1 has been implicated in various diseases, including cancers (e.g., hepatocellular carcinoma, gastric cancer, glioblastoma) and neurodevelopmental disorders. Research using METTL1 antibodies has revealed its role in promoting tumor progression, metastasis, and therapy resistance by modulating oncogenic signaling pathways and mRNA translation. The antibody is widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect METTL1 expression levels, subcellular localization, and interactions in cell lines, tissues, or clinical samples. Validated METTL1 antibodies (often raised in rabbits or mice as monoclonal or polyclonal forms) are crucial for exploring its biological functions, disease associations, and potential as a therapeutic target. Recent studies also highlight its involvement in stem cell differentiation and immune responses, underscoring its broad relevance in molecular and translational research.